Cósmico Health

Platform analyzing blood biomarkers to provide actionable health and performance insights.

Cover Block

From the public record

Field	Value
Name	Cósmico Health
Tagline	Platform analyzing blood biomarkers to provide actionable health and performance insights.
Headquarters	Salamanca
Founded	2024
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder

The Short Version

PUBLIC Cósmico Health is an early-stage Spanish healthtech company building a consumer platform that interprets blood biomarkers into practical health and performance guidance, and it merits attention now because the public record shows an active build phase, an incubator affiliation, and early hiring around the core product [LinkedIn, September 2026] [cosmicohealth.com] [es.jooble.org]. Founded in 2024 in Salamanca, the company presents itself as a preventive-health business aiming to make biomarker tracking part of routine life rather than a tool used only in clinical settings, a framing that places it alongside a broader shift toward consumerized diagnostics and longitudinal health monitoring [LinkedIn, September 2026].

The product claim is straightforward: Cósmico says it translates complex blood-test data into understandable, actionable recommendations and connects the user with doctors, laboratories, and day-to-day behavior through a single AI-enabled app [LinkedIn, September 2026] [cosmicohealth.com]. That is a credible wedge at the concept level, but the public evidence still points to a company in construction rather than deployment, with LinkedIn stating that the technology platform is still being built and that the team is seeking a full-stack developer [LinkedIn, September 2026].

The founding bench appears centered on Javier Moretón Díaz, identified publicly as the founder, with prior experience at Centro de Día Geriasol, Atulado, Psiconómada, and Willis Towers Watson according to RocketReach and supporting context from Atulado's company description [rocketreach.co] [LinkedIn, 2026]. That background reads as more adjacent to care delivery, socio-health services, and benefits-related operating context than to a previously visible venture-backed diagnostics play, which is neither a negative nor a proof point, but it does frame execution risk around productization and go-to-market [rocketreach.co] [LinkedIn, 2026].

On capitalization, no confirmed public funding round, lead investor, or valuation appears in the available record, while the company does state that it is incubated at Abioinnova [LinkedIn, September 2026]. com].

Unconfirmed -- This section relies primarily on company-controlled materials and a founder directory profile, with limited independent corroboration beyond public profile data.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder

The Company in Brief

PUBLIC Cósmico Health presents as a very early Spanish preventive-health startup, with the public record still confined mostly to its own materials. The company says it was founded in 2024 and is based in Salamanca, and its website describes the core product as a platform that interprets blood biomarkers for health and performance decisions [cosmicohealth.com]. The same site frames the product around linking users, physicians, laboratories, and day-to-day behavior through a single AI-enabled app [cosmicohealth.com].

The chronology is short but reasonably clear on first principles. The company states that it is incubated at Abioinnova and that it is still building the technology platform, which suggests the business remains in product-development mode rather than broad commercial rollout [LinkedIn, September 2026]. Public materials also indicate active hiring for technical buildout, including a search for a full-stack developer, which is consistent with an early formation stage [LinkedIn, September 2026].

Founder identity is less cleanly documented in primary company material than the product concept itself. Javier Moretón Díaz is identified as founder in a RocketReach profile, but that attribution is not visible in the company website cited for this section, and no legal entity detail is confirmed in the cited sources here [rocketreach.co]. On the evidence available from company materials, the most defensible reading is that Cósmico Health is a 2024-founded Salamanca startup still assembling its platform, with Abioinnova as its clearest publicly named institutional affiliation [cosmicohealth.com] [LinkedIn, September 2026].

Unconfirmed -- This section relies primarily on company website and company profile claims, with no cited state filing or independent registry corroboration in the evidence used here.

What They Have Built

MIXED

The product claim is straightforward, even if the underlying system is still early. Cósmico Health describes itself as a preventive-health platform built around blood biomarkers, with the stated aim of turning complex lab results into understandable, actionable guidance for health and performance decisions [LinkedIn, September 2026]. On its website, the company adds a more specific workflow claim, saying the app connects the user with their doctor, laboratories, and daily life through a single AI-enabled interface [cosmicohealth.com]. Public materials also say the company is still building the technology platform, which matters because it places the product today closer to an announced solution than a verified, launched system with documented usage [LinkedIn, September 2026].

The practical differentiation, based on what is publicly described, appears to rest less on novel hardware or diagnostics and more on interpretation and user translation. The company frames biomarkers as something that should become routine rather than reserved for clinical moments, which suggests a consumer-facing software layer that sits on top of existing blood testing rather than replacing laboratories or physicians [LinkedIn, September 2026]. That positioning is plausible in preventive health, but the public record reviewed here does not show a verified demo, named integration partners, published clinical validation, or evidence that the AI layer has been tested at scale [LinkedIn, September 2026] [cosmicohealth.com].

A small hiring footprint supports the view that the technical organization is still being assembled. LinkedIn says the company is seeking a full-stack developer, and a separate job listing references a CTO / Full-Stack Developer role, which points to an early build stage rather than an already staffed product and engineering function [LinkedIn, September 2026] [es.jooble.org]. Beyond that, any conclusion about the stack would be speculative, so the only defensible inference is that core application development remains in progress (inferred from job postings) [LinkedIn, September 2026] [es.jooble.org].

Unconfirmed -- This section relies primarily on company-controlled sources, including the company LinkedIn profile and website, with limited corroboration from a third-party job listing.

Market Size and Demand

Market context

PUBLIC The market matters now because preventive health is moving from annual checkups and one-off lab work toward continuous, consumer-facing interpretation, but the public evidence around Cósmico Health points to category timing more than company-specific traction [LinkedIn, September 2026].

The immediate problem the company is trying to address is legibility, not access alone. Its public description centers on turning blood biomarker results into understandable, actionable guidance, and on making biomarkers part of routine decision-making rather than something reserved for clinical settings [LinkedIn, September 2026]. That places it in the overlap between consumer wellness, digital health interpretation, and laboratory-data navigation, a real market need in principle, even if no third-party TAM, SAM, or SOM figures were provided in the source set.

Because no named market-sizing report was supplied, any sizing discussion here has to remain directional. The closest analogous public frame available in the research is the preventive-health category represented by Neko Health and Function Health, which were surfaced as relevant comparators in broader coverage of the sector rather than as direct evidence about Cósmico Health itself [TechCrunch, October 2026]. On that basis, the addressable spend appears to sit across adjacent consumer budgets, including routine lab testing, wellness subscriptions, performance optimization, and digital health tools, but the current source base does not support a quantified market estimate.

The demand drivers visible from public materials are straightforward. Consumers are more accustomed to managing health data in app form, laboratories already produce dense biomarker output that many users struggle to interpret, and founders across the category are trying to reposition testing from episodic diagnosis toward ongoing prevention and performance monitoring [LinkedIn, September 2026] [TechCrunch, October 2026]. For a company like Cósmico Health, that creates a plausible tailwind if it can prove that interpretation, user experience, and physician connectivity matter as much as the underlying test itself.

Adjacent markets and external forces

PUBLIC The more useful way to read this market is as a convergence of several adjacent categories rather than a single clean segment.

Cósmico Health sits near at least three substitutes or neighboring markets. One is direct-to-consumer preventive screening, where the product decision begins with a health-conscious individual rather than a provider referral [TechCrunch, October 2026]. Another is digital health software that organizes results and nudges behavior change through an app layer, which aligns with the company website's claim that it connects users with doctors, laboratories, and daily life through a single AI-enabled application [cosmicohealth.com]. A third is broader wellness and performance tracking, where users may compare blood biomarkers with wearables, nutrition programs, and coaching products as alternative ways to guide decisions.

That positioning has implications for both demand and risk. On the positive side, consumers already spend on adjacent categories without waiting for reimbursement, which can make a B2C wedge viable at small scale. The constraint is that substitute products are plentiful, and public materials do not yet show whether Cósmico Health competes primarily on interpretation quality, clinical integration, convenience, or a lower-friction acquisition path.

Regulatory and macro forces cut both ways. Health data handling, medical claims, and the line between wellness guidance and regulated clinical decision support all matter in this category, especially for any product translating biomarker information into recommendations. The sources provided do not document a regulatory pathway, certification, or reimbursement strategy for Cósmico Health, so the prudent reading is that category expansion may be strong while execution requirements remain high [LinkedIn, September 2026] [cosmicohealth.com].

Market lens	Public support	Relevance to Cósmico Health
Preventive health platforms	Sector context discussed through Neko Health and Function Health [TechCrunch, October 2026]	Suggests investor and consumer interest in prevention-oriented health products
Biomarker interpretation software	Company describes a platform based on blood biomarker analysis [LinkedIn, September 2026]	Core product category implied by the public company profile
Consumer wellness and performance tools	Company frames output as actionable health and performance insights [LinkedIn, September 2026]	Expands the potential user motivation beyond illness detection alone
Health data coordination apps	Website says the app connects users with doctors, laboratories, and daily life [cosmicohealth.com]	Points to a workflow layer, not only a test-result dashboard

The table shows a market story that is coherent but still loosely evidenced. The category logic is visible in public sources, yet the absence of third-party market sizing means investors should treat the opportunity as qualitatively attractive rather than quantitatively underwritten at this stage.

Unconfirmed -- This section relies primarily on company and LinkedIn descriptions, with limited independent sector context from TechCrunch and no cited third-party market sizing report.

Who Else Is Fighting for This

MIXED Cósmico Health is positioning itself against a better-capitalized preventive-health field by narrowing the promise to biomarker interpretation for everyday health decisions, rather than trying to own the full stack of diagnostics, clinics, and consumer wellness from day one [LinkedIn, September 2026] [cosmicohealth.com].

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Cósmico Health	Spanish preventive-health platform analyzing blood biomarkers and translating lab data into actionable health and performance guidance for consumers [PUBLIC]	Founded 2024; no confirmed public funding round identified in the cited materials [PUBLIC]	Connects users with doctor, laboratories, and daily life through one app, according to the company; currently building the platform [PUBLIC]	[LinkedIn, September 2026] [cosmicohealth.com]
Neko Health	Preventive-health company referenced in broader market coverage tied to preventive health [PUBLIC]	Stage / funding not established in the provided materials [PUBLIC]	Public visibility in preventive-health discussions gives it category awareness that smaller entrants may lack [PUBLIC]	[TechCrunch, October 2026]
Function Health	Preventive-health company referenced in broader market coverage tied to preventive health [PUBLIC]	Stage / funding not established in the provided materials [PUBLIC]	Public visibility in biomarker-led preventive health, based on cited market discussion [PUBLIC]	[TechCrunch, October 2026]

The field breaks into three practical groups. Incumbents are conventional laboratories, physicians, and clinic-led care pathways that already own blood testing and clinical trust, even if they do not package results as an ongoing consumer product. Challengers include biomarker-led preventive-health startups such as Neko Health and Function Health, which appear in category coverage and help define consumer expectations around proactive screening and longitudinal health tracking [TechCrunch, October 2026]. Adjacent substitutes include generic wellness apps and any service that helps consumers interpret health data, even if blood biomarkers are only one input rather than the center of the product [cosmicohealth.com].

Cósmico Health's clearest edge today is not scale, capital, or regulatory position. It is focus. The company is describing a narrower workflow, turning complex blood-test data into understandable guidance and connecting that guidance to doctors, laboratories, and daily life through one application [LinkedIn, September 2026] [cosmicohealth.com]. That can be useful if the product reduces friction between a lab result and a behavior change, but the edge looks perishable rather than durable at this stage because the cited materials do not yet show proprietary datasets, exclusive lab relationships, clinical validation, or a distribution channel the company uniquely controls [LinkedIn, September 2026] [cosmicohealth.com].

The exposure is easier to see than the moat. A named competitor such as Function Health has an advantage if the category rewards brand recognition and consumer willingness to trust a recognized preventive-health name with sensitive biomarker data [TechCrunch, October 2026]. Neko Health is also better placed if the winning model depends on an integrated screening experience rather than software layered onto third-party lab work, although the provided materials here do not establish its operating model in detail and that inference should be treated cautiously [TechCrunch, October 2026]. Closer to home, Cósmico Health does not appear to own the lab channel, the physician channel, or a disclosed employer distribution channel based on the available public record, which limits how quickly it can defend customer acquisition if larger players enter Spain or broader Western Europe [LinkedIn, September 2026].

The most plausible 18-month scenario is a sorting of the category by distribution rather than product language alone. Winner if trust and distribution matter most: Function Health, because visible category presence tends to compound in consumer health once acquisition costs rise and consumers favor known brands [TechCrunch, October 2026]. Loser if execution slips while the platform is still being assembled: Cósmico Health, because the public record still describes the product as in build mode and shows active hiring for technical talent, which usually signals that core product delivery is still ahead rather than behind the team [LinkedIn, September 2026] [es.jooble.org].

Inferred, not confirmed -- This section relies on company materials for Cósmico Health's positioning and on a single TechCrunch market reference for named competitors; competitor funding, scale, and operating details were not established in the provided source set.

Opportunity

PUBLIC The prize here is straightforward: if Cósmico Health can turn bloodwork from a one-off lab report into a recurring consumer health interface, it could become a Spanish-language preventive-health platform with value far beyond a single app feature set [LinkedIn, September 2026] [cosmicohealth.com].

The headline opportunity rests on a narrow but meaningful public signal. The company is not presenting itself as a generic wellness app, it is framing the product around blood biomarkers and the translation of complex test results into actionable guidance, with the stated aim of making biomarkers part of everyday health management rather than something used only in clinical settings [LinkedIn, September 2026]. That positioning matters because consumer interest in proactive screening has already produced visible category leaders, including Neko Health and Function Health, which TechCrunch identified in broader preventive-health coverage in October 2026 [TechCrunch, October 2026]. On the evidence available, the reachable upside is not that Cósmico Health becomes a full-stack care provider overnight. It is that it becomes the software layer that helps consumers interpret, revisit, and act on longitudinal biomarker data, starting with a focused geography and language context where incumbents are less entrenched in local distribution [LinkedIn, September 2026] [cosmicohealth.com].

The plausible paths to scale are still conditional, but they can be stated plainly from the public record.

Scenario	What happens	Catalyst	Why it's plausible
Consumer biomarker subscription	The company launches a repeat-use product around recurring blood analysis, interpretation, and follow-up guidance for individuals focused on prevention and performance	A working product launch that converts the current platform-building phase into a paid consumer service [LinkedIn, September 2026]	The company already frames biomarkers as a routine health tool and says it is actively building the platform, which supports a subscription-style use case if users return for repeat testing over time [LinkedIn, September 2026]
Health coordination layer	The app becomes a lightweight coordination layer between the user, laboratories, and physicians, making it more useful than a static lab-result viewer	A lab integration or doctor workflow that operationalizes the website claim that the app connects users with their doctor and laboratories [cosmicohealth.com]	The company's own product description already centers on connecting those parties in one app; if implemented, that creates a broader workflow than interpretation alone [cosmicohealth.com]
Iberian preventive-health brand	The company establishes early consumer trust in Spain and nearby markets, then expands as a regional preventive-health brand anchored in biomarker literacy	Support from incubation at Abioinnova and successful early hiring to complete the technical core [LinkedIn, September 2026] [es.jooble.org]	Incubation and recruiting do not prove traction, but they do indicate an organized effort to build a product rather than a concept page, which is the minimum starting point for regional brand formation [LinkedIn, September 2026] [es.jooble.org]

What compounding would look like here is a data-and-engagement flywheel rather than a classic social network effect. If users upload or generate repeat blood panels, the product can build longitudinal baselines, make recommendations more context-aware, and increase the practical value of staying inside the app for the next test cycle. If the app also becomes the place where users connect lab results with physician conversations and daily behavior, switching costs rise because the record becomes cumulative rather than episodic [cosmicohealth.com] [LinkedIn, September 2026]. The public evidence does not yet show that this flywheel has started, but the company's stated architecture points in that direction: a single app, AI-mediated interpretation, and explicit linkage between laboratory data, doctors, and everyday life [cosmicohealth.com].

The size of the win is easiest to frame through category comparables, while staying conservative about what they do and do not prove. TechCrunch's October 2026 preventive-health coverage treated Neko Health and Function Health as relevant reference points for consumer-facing biomarker and screening businesses, which is enough to establish that investors and media already recognize this as a venture-scale category rather than a niche service line [TechCrunch, October 2026]. If Cósmico Health were to emerge as a credible regional leader in consumer biomarker intelligence, the outcome could support a meaningful venture-scale valuation (scenario, not a forecast), not because current traction supports that today, but because the category has shown the capacity to produce large, branded consumer health platforms when interpretation, trust, and repeat engagement come together [LinkedIn, September 2026] [TechCrunch, October 2026]. The missing piece in public evidence is execution proof: launch, usage, repeat testing behavior, and any sign of paid conversion.

Unconfirmed -- This section relies primarily on company LinkedIn and website claims, with TechCrunch used only to support category relevance rather than company-specific traction.

Sources